Multiple sclerosis – pipeline review, h2 2012


Published on

Aarkstore Enterprise-Multiple sclerosis – pipeline review, h2 2012

Published in: Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Multiple sclerosis – pipeline review, h2 2012

  1. 1. announces, The Latest market research report is available inits vast collection:Multiple Sclerosis – Pipeline Review, H2 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Multiple Sclerosis - Pipeline Review, Global MarketsDirect’s, Multiple Sclerosis - Pipeline Review, H2 2012, provides an overview of theindication’s therapeutic pipeline. This report provides information on thetherapeutic development for Multiple Sclerosis, complete with latest updates, andspecial features on late-stage and discontinued projects. It also reviews key playersinvolved in the therapeutic development for Multiple Sclerosis. Multiple Sclerosis -Pipeline Review, Half Year is built using data and information sourced from GlobalMarkets Direct’s proprietary databases, Company/University websites, SEC filings,investor presentations and featured press releases from company/university sitesand industry-specific third party sources, put together by Global Markets Direct’steam.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Multiple Sclerosis.
  2. 2. - A review of the Multiple Sclerosis products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Multiple Sclerosis.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.Table of contents:List of Tables 6List of Figures 10Introduction 11Global Markets Direct Report Coverage 11Multiple Sclerosis Overview 12Therapeutics Development 13An Overview of Pipeline Products for Multiple Sclerosis 13Multiple Sclerosis Therapeutics under Development by Companies 15Multiple Sclerosis Therapeutics under Investigation by Universities/Institutes 27Late Stage Products 31Comparative Analysis 31Mid Clinical Stage Products 32Comparative Analysis 32Early Clinical Stage Products 33Comparative Analysis 33Discovery and Pre-Clinical Stage Products 34Comparative Analysis 34Multiple Sclerosis Therapeutics – Products under Development by Companies 35Multiple Sclerosis Therapeutics – Products under Investigation byUniversities/Institutes 40Companies Involved in Multiple Sclerosis Therapeutics Development 42Alcon, Inc. 42Genzyme Corporation 43
  3. 3. Baxter International Inc. 44F. Hoffmann-La Roche Ltd. 45Abbott Laboratories 46Biogen Idec Inc. 47Amgen Inc. 48Eli Lilly and Company 49Athersys, Inc. 50List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012 Review, H22012&PubId=&pagenum=1 Liver Cancer – Pipeline Review, H2 2012 Non-Small Cell Lung Cancer – Pipeline Review, H2 2012 Asthma – Pipeline Review, H2 2012 Multiple Sclerosis – Pipeline Review, H2 2012 Gastrointestinal Tract Cancer – Pipeline Review, H2 2012 Diabetes – Pipeline Review, H2 2012 Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,
  4. 4. H2 2012 Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012 Malaria – Pipeline Review, H2 2012 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,H2 2012 Dermatitis – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: